SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).

被引：8

作者：

Garralda, Elena

Sanborn, Rachel E.

Minchom, Anna Rachel

Davar, Diwakar

Curigliano, Giuseppe

Ribrag, Vincent

Mehta, Amitkumar

Foss, Francine M.

Zain, Jasmine M.

Forero-Torres, Andres

Ansell, Stephen M.

机构：

[1] Hosp Vall dHebron, Barcelona, Spain

[2] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA

[3] Royal Marsden Hosp, Drug Dev Unit, London, England

[4] Inst Canc Res, London, England

[5] Hillman Canc Ctr, Pittsburgh, PA USA

[6] IRCCS, European Inst Oncol, Milan, Italy

[7] Univ Milano, Milan, Italy

[8] Gustave Roussy Inst, Villejuif, France

[9] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA

[10] Yale New Haven Hosp, 20 York St, New Haven, CT 06504 USA

[11] City Hope, Duarte, CA USA

[12] Seagen Inc, Bothell, WA USA

[13] Mayo Clin, Rochester, MN USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS2657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2657

引用

页数：3